Tirzepatide helps people lose weight, which eases strain on the heart and blood vessels
Clinical trial data shows meaningful weight loss in the first 12 weeks of GLP-1 treatment, though results vary significantly based on starting weight, the specific medication, dose, dietary choices, and activity level
Wegovy tablets and injections are FDA-approved in adults for: weight loss and weight management in adults with obesity or adults who are overweight and have a weight-related medical problem (e.g., blood pressure, type 2 diabetes, or high cholesterol) reducing major cardiovascular event risks (such as heart attack, stroke, or death) in adults with established CV disease and either obesity or overweight Wegovy injection is also FDA-approved for: weight loss and weight management patients with obesity who are 12 years and older non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), this is an accelerated approval
During these exclusivity periods, no other company can manufacture or sell the same active ingredient without the patent holder's permission
